Vergoeding 2017-2021 voor ATC-subgroep L04AA : Selectieve immunosuppressiva
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| L04AA06 Mycofenolzuur (Cellcept ®) | 11.030.400 | 10.950.600 | 11.741.000 | 11.758.700 | 9.552.200 |
| L04AA10 Sirolimus (Rapamune ®) | 1.454.800 | 1.458.200 | 1.487.500 | 1.456.900 | 1.463.800 |
| L04AA13 Leflunomide (Arava ®) | 1.924.600 | 2.039.400 | 2.336.100 | 1.081.900 | 1.288.500 |
| L04AA18 Everolimus (Certican ®) | 4.297.000 | 4.946.800 | 5.270.100 | 4.997.900 | 4.828.000 |
| L04AA27 Fingolimod (Gilenya ®) | 24.380.400 | 27.140.800 | 27.466.100 | 25.303.800 | 25.242.300 |
| L04AA31 Teriflunomide (Aubagio ®) | 10.976.800 | 12.681.800 | 14.052.400 | 15.093.400 | 15.718.800 |
| L04AA38 Ozanimod (Zeposia ®) | . | . | . | 1.441 | 1.192.200 |
| L04AA40 Cladribine (Mavenclad ®) | . | 2.290.500 | 4.653.000 | 3.939.500 | 5.276.400 |
| L04AA42 Siponimod (Mayzent ®) | . | . | . | . | 1.370.300 |
| L04AA Selectieve immunosuppressiva | . | . | . | . | 157 |
| Totaal | 54.064.000 | 61.508.100 | 67.006.200 | 63.633.541 | 65.932.657 |